Ameliorated inflammation of alveolar and lung interstitial, suppressed pulmonary fibrosis, down-regulated IFN-γ levels in serum and TGF-β, NF-κB, CTGF, ERK1/2, and FasL. The gene discussed is MAPK3; the disease is pulmonary fibrosis.